Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genomically Directed Therapy in Triple Negative Breast Cancer (BRE12-158)
NCT02101385Phase 2Completed
- Sponsor
- Bryan Schneider
- Start
- Apr 2014
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple negative breast cancer (TNBC), sponsored by Bryan Schneider. Started Apr 2014; status: completed.
02
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02101385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101385.